Details

Autor(en) / Beteiligte

• Fajadet, Jean
• Wijns, William
• Laarman, Gert-Jan
• Kuck, Karl-Heinz
• Ormiston, John
• Baldus, Stephan
• Hauptmann, Karl E
• Suttorp, Maarten J
• Drzewiecki, Janusz
• Pieper, Michael
• Schultheiss, Heinz-Peter
• Mauri, Laura

Titel

Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study

Ist Teil von

• EuroIntervention, 2010-11, Vol.6 (5), p.562-567

Ort / Verlag

France

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• We report here the final 5-year follow-up results from the ENDEAVOR II trial, which was the first randomised trial evaluating the Endeavor(tm) zotarolimus-eluting stent (ZES) compared with a bare metal stent (BMS) in patients with single, de novo coronary artery lesions. Eligible patients were randomised 1:1 to receive ZES or BMS and were followed by telephone or clinic visit up to five years. We evaluated TVF and its components (target vessel revascularisation [TVR], Q-wave or non Q-wave myocardial infarction, or cardiac death attributed to the target vessel) at five years. Additionally, we report rates of MACE, TLR, and stent thrombosis (protocol- and ARC-defined) through five years. ENDEAVOR II enrolled 1,197 patients (598 ZES, 599 BMS). At five years of follow-up, the rates of TVF (15.4% vs 24.4%), TVR (10.7% vs 20.1%), MACE (15.4% vs 24.6%), and TLR (7.5% vs 16.3%) remained significantly lower in ZES patients compared with BMS patients. ARC definite and probable very late (>1 year) stent thrombosis remained low (0.2% ZES and 0.3% BMS) through five years. After five years of follow-up, ZES demonstrated significantly improved clinical outcomes with sustained safety compared with BMS in patients with obstructive coronary artery disease.